Trial Profile
Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2022
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary) ; Enoxaparin sodium; Glycoprotein inhibitors; Heparin
- Indications Acute coronary syndromes; Myocardial infarction; Thrombosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EUROMAX
- Sponsors The Medicines Company
- 07 Nov 2022 Results of pooled subgroup analysis (n=15254) assessing efficacy of bivalirudin versus heparin in patients with STEMI undergoing PCI from BRIGHT, EUROMAX, HEAT-PPCI, HORIZONS-AMI, MATRIX, and VALIDATE-SWEDEHEART studies, presented at the American Heart Association Scientific Sessions 2022.
- 01 Dec 2017 Results of age-based subgroup analysis assessing the effect of bivalirudin versus heparin using 30-day pooled data (n=5800) from the two large randomized trials (EUROMAX and HORIZONS-AMI), published in the American Heart Journal.
- 17 Oct 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.